Edwards Lifesciences's EBIT per Share for the
three
months ended in Mar. 2026 was CHF0.70.
Its EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 was CHF1.91.
During the past 12 months, the average EBIT per Share Growth Rate of Edwards Lifesciences was 15.90% per year.
During the past 3 years, the average EBIT per Share Growth Rate was 4.20% per year.
During the past 5 years, the average EBIT per Share Growth Rate was 4.10% per year.
During the past 10 years, the average EBIT per Share Growth Rate was 10.00% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for Edwards Lifesciences's EBIT per Share or its related term are showing as below:
XSWX:EW'
s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -25 Med: 14.65 Max: 82.9
Current: 4.2
During the past 13 years, the highest 3-Year average EBIT per Share Growth Rate of Edwards Lifesciences was 82.90% per year. The lowest was -25.00% per year. And the median was 14.65% per year.
XSWX:EW's 3-Year EBIT Growth Rate is ranked worse than 57.68% of 690
companies
in the Medical Devices & Instruments industry
Industry Median: 9.65
vs XSWX:EW: 4.20
Edwards Lifesciences (XSWX:EW) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
Edwards Lifesciences EBIT per Share Related Terms
Edwards Lifesciences EBIT per Share Historical Data
* Premium members only.
The historical data trend for Edwards Lifesciences's EBIT per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was CHF1.91
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Edwards Lifesciences (XSWX:EW) has a EBIT per Share of CHF1.91 as of Mar. 2026. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Edwards Lifesciences and its competitors. According to the industry distribution chart, Edwards Lifesciences ranks #398 out of 690 companies in the Medical Devices & Instruments industry, placing it in the top 57.7%.
Is Edwards Lifesciences' EBIT per Share too high?
Edwards Lifesciences' current EBIT per Share is CHF1.91. Based on the distribution chart, Edwards Lifesciences ranks #398 out of 690 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Edwards Lifesciences has a GF Score™ of 97/100, reflecting its overall financial health beyond just this single metric.
How does Edwards Lifesciences' EBIT per Share compare to DXCM and GEHC?
According to the Medical Devices & Instruments industry distribution chart, Edwards Lifesciences ranks #398 out of 690 companies for EBIT per Share. This places Edwards Lifesciences in the lower half of its industry. The industry median EBIT per Share is 9.65. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Medical Devices & Instruments company?
The median EBIT per Share among Medical Devices & Instruments companies is 9.65, based on 690 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Edwards Lifesciences and its competitors. For the Medical Devices & Instruments industry, the median EBIT per Share is 9.65 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Edwards Lifesciences's current EBIT per Share is CHF1.91. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Edwards Lifesciences stock overvalued right now?
Edwards Lifesciences (XSWX:EW) has a current EBIT per Share of CHF1.91. The stock's GF Value™ is CHF75.73, compared to a current price of CHF72.91 — trading 3.7% below its estimated fair value. The current EBIT per Share is CHF1.91. Edwards Lifesciences' overall GF Score™ is 97/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For Edwards Lifesciences (XSWX:EW), the current EBIT per Share is CHF1.91 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Edwards Lifesciences (XSWX:EW) Overvalued in 2026?
Based on GuruFocus' analysis, Edwards Lifesciences stock appears to be undervalued.
The current stock price of CHF72.91 is trading 3.7% below its estimated GF Value™ of CHF75.73.
Key valuation signals for XSWX:EW:
EBIT per Share: CHF1.91
GF Value™: CHF75.73 vs. price of CHF72.91 (3.7% below fair value)
No single metric tells the full story. See the XSWX:EW stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Spun off from Baxter International in 2000, Edwards Lifesciences designs, manufactures, and markets a range of medical devices and equipment for advanced stages of structural heart disease. It has established itself as a leader across key products, including surgical tissue heart valves, transcatheter aortic valves, and transcatheter mitral and tricuspid valve technologies. The firm derives about 60% of its total sales from outside the US.
97GF Score
Get the complete analysis for XSWX:EW
EBIT per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:EW has been successfully added to your 
